Chimeric Therapeutics (CHM) 2025 Extraordinary General Meeting Transcript

Summary of Chimeric Therapeutics (CHM) 2025 Extraordinary General Meeting Company Overview - Company: Chimeric Therapeutics (CHM) - Meeting Date: July 22, 2025 - Location: Online meeting hosted from Victoria, Australia Key Points and Arguments Financial Performance - Fundraising: Raised $16.6 million during FY 2025, including $5.6 million from a US Family Office [7] - Debt Management: The Lindt facility will be fully paid out, marking a significant financial milestone [7] Clinical Development Updates - CHM CDH 17: - Trial commenced late last year with five patients treated. - Best result: One patient with stable disease after six months [9] - Manufacturing success: Eight out of eight successful runs, indicating strong operational capabilities [10] - CHM CoreNK: - Transitioned to frontline setting for the ADVENT AML study. - Achieved two complete responses with no signs of leukemia in patients [10][14] Resolutions and Voting Outcomes - Resolution 1: Ratification of the issuance of 164.3 million first tranche placement shares. - Proxy votes: 86% in favor, 14% against [18] - Resolution 2: Approval to issue up to 1.485 billion second tranche placement shares. - Proxy votes: 85% in favor, 15% against [20] - Resolution 3: Approval to issue up to 1.65 billion attaching options. - Proxy votes: 79% in favor, 21% against [22] - Resolution 4: Approval to issue 25 million adviser options for professional services. - Proxy votes: 79% in favor, 21% against [24] - Resolution 5A and 5B: Approval to issue 141.25 million shares and options to Lind. - Proxy votes: 73% in favor, 27% against [26] Meeting Logistics - Voting Process: Conducted via a poll, with results to be announced on the ASX later that day [6][30] - Q&A Session: No questions were raised during the meeting, indicating either satisfaction with the presented information or a lack of engagement from attendees [29] Additional Important Information - Management Acknowledgment: The meeting included acknowledgments of traditional custodians of the land, reflecting the company's commitment to cultural respect [1] - Operational Efficiency: Significant headcount and cost reductions were noted, contributing to improved business operations [8] This summary encapsulates the critical aspects of the meeting, highlighting the company's financial health, clinical advancements, and shareholder engagement through resolutions and voting outcomes.